Navigation Links
Data on VELCADE(R) (Bortezomib) for Injection Based Therapies to be Presented at the International Myeloma Workshop
Date:2/23/2009

ADE in the U.S., Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. VELCADE is approved in more than 87 countries worldwide.

Important Safety Information

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma. VELCADE also is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension throughout therapy, cardiac and pulmonary disorders, reversible posterior leukoencephalopathy syndrome, gastrointestinal adverse events, thrombocytopenia, neutropenia, tumor lysis syndrome and hepatic events. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Nursing mothers are advised not to breastfeed while receiving VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with no risk factors for decreased left ventricular ejection fraction. There have been reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients receiving VELCADE. Some of these events have been fatal. There have been reports of Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in patients
'/>"/>

SOURCE Millennium: The Takeda Oncology Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
2. Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
3. Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
4. VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
5. Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
6. Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy
7. FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
8. Inexpensive and Illegal Buttock - Boosting Injections Not Pretty
9. Radiofrequency treatment better than ethanol injection for small liver tumors
10. Bedford Laboratories(TM) to Begin Shipping Irinotecan HCl Injection
11. Cosmetic Injections A Worthwhile Investment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, iFitDress.com, the ... for women, has announced its new selection of black ... are on sale now; they are available at discounted prices, ... says, “The promotion will last for three weeks only. You ... market. Those who are interested in our new items can ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the business ... company announces big discounts on its bamboo mats ... BambooFlooringChina.com is the world’s leader in bamboo flooring. According ... Jan. 20, 2015. , The bamboo mats are made ... thread. All the bamboo strips for the mats are ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... chronic illnesses can receive effective, less expensive care from a ... to a team of dedicated health care professionals, a new ... ill and need either hospitalization or a trip to the ... home clinic at the University of Texas in Houston versus ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... on a "fountain of youth" drug that can delay the ... a new study suggests. Seniors received a significant boost ... a genetic signaling pathway linked to aging and immune function, ... The experimental medication, a version of the drug rapamycin, improved ...
(Date:12/25/2014)... 25, 2014 Plugin creators from Pixel ... A fully customizable business presentation tool made specifically for ... ProFire 5k business tool, users can now display their ... of Pixel Film Studios. “ProFire 5k gives users a ... add professionalism to a presentation” , Pixel Film Studios ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... , CUPERTINO, Calif., Sept. 17 DURECT ... scheduled to present at two upcoming healthcare conferences. , , ... , Matt Hogan, Chief Financial Officer, will ... on Wednesday, September 23rd at 10:30 a.m. Eastern Time. A ...
... , , MOUNTAIN VIEW, ... first and leading providers of kidney dialysis services and a ... The Polycystic Kidney Disease Foundation,s "Pathway to a Cure" walk ... held Sunday, September 20, 2009 at The Capital Building, 1315 ...
... , , , ... Somanetics Corporation (Nasdaq: SMTS ) today reported net revenues ... percent increase from $12.4 million in the same period of 2008. For ... $35.5 million from $33.8 million. , , U.S. net revenues ...
... , , , ... of a plan to expand its brand, Nutrisystem Inc., (Nasdaq: ... market Nutrisystem J Diet in Japan. Capitalizing on the success of Nutrisystem ... North America, House Foods will begin to sell Nutrisystem J Diet in ...
... , , , ... is an important time for families and eyesight, as many schools ... With the start of a new school year, it,s also a ... the environment and establish every day green habits. With this in ...
... , , , ... management provider Avizent announced today that Adrienne Paler, Executive Vice President ... the Disability Management Employer Coalition (DMEC). , , ... to the organization. Ms. Paler worked to write and enhance ...
Cached Medicine News:Health News:DURECT Corporation to Participate in Upcoming Healthcare Conferences 2Health News:Satellite Healthcare Helps Support the Cure for Kidney Disease in Sacramento 2Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 2Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 3Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 4Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 5Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 6Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 7Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 8Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 9Health News:Nutrisystem and House Foods Announce Licensing Agreement To Market Nutrisystem J Diet in Japan 2Health News:Nutrisystem and House Foods Announce Licensing Agreement To Market Nutrisystem J Diet in Japan 3Health News:Back to School Season is Time for New Green Routines 2Health News:Back to School Season is Time for New Green Routines 3Health News:Avizent Executive Earns DMEC Partnership Award 2
(Date:12/24/2014)... DIEGO , Dec. 23, 2014 ResMed (NYSE: ... significant patent infringement action against Chinese medical device manufacturer BMC ... (ITC) ruled today that BMC,s masks listed below infringe ResMed,s ... or selling these masks in the United States ... iVolve N2 nasal mask , Willow nasal pillows mask ...
(Date:12/24/2014)... ALEXANDRIA, Va. , Dec. 23, 2014 /PRNewswire-USNewswire/ ... stringent diastolic blood pressure target for people with ... either moderate or high doses of statins, in ... risk management enacted by the American College of ... recommendations are reflected in the most recent changes ...
(Date:12/22/2014)... 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical care ... technology to help fight deadly inflammation in critically-ill ... today announced the appointment of Dr. Gregory ... Senior Vice President of Clinical Development, effective January ... Russo is an accomplished pediatric cardiothoracic surgeon ...
Breaking Medicine Technology:ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... 22, 2011 AuraSense Therapeutics, a biopharmaceutical ... as gene regulation- and chemo-therapeutics for a ... dermatology, neurology, and for cardiovascular disorders, has ... Abbott Biotech Ventures, a subsidiary of Abbott.  ...
... The Myth that physicians workload lessens its ... the New Year quickly approaching physicians are preparing for some ... depicts Healthcare IT spending by physicians and other healthcare is ... year, with most of it attributed to electronic health record ...
Cached Medicine Technology:AuraSense Therapeutics Secures Series B Equity Investment 2Medicalbillersandcoders.com Puts its Service Offers to Physicians Who Strive to Streamline Their Practice This Holiday Season! 2Medicalbillersandcoders.com Puts its Service Offers to Physicians Who Strive to Streamline Their Practice This Holiday Season! 3Medicalbillersandcoders.com Puts its Service Offers to Physicians Who Strive to Streamline Their Practice This Holiday Season! 4
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... chairs are recommended for the following ... static control, health care and office. ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTC/1Q chairs are recommended for the ... room, static control, health care and ...
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
Medicine Products: